Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Shares Issued (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Shares Issued for 5 consecutive years, with $8.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued rose 215.29% year-over-year to $8.6 million, compared with a TTM value of $40.8 million through Dec 2025, up 136.25%, and an annual FY2025 reading of $40.8 million, up 136.25% over the prior year.
  • Shares Issued was $8.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $16.3 million in the prior quarter.
  • Across five years, Shares Issued topped out at $16.3 million in Q3 2025 and bottomed at $510000.0 in Q1 2023.
  • Average Shares Issued over 5 years is $3.6 million, with a median of $1.3 million recorded in 2021.
  • The sharpest move saw Shares Issued plummeted 78.77% in 2022, then skyrocketed 1022.91% in 2025.
  • Year by year, Shares Issued stood at $1.2 million in 2021, then rose by 6.44% to $1.3 million in 2022, then decreased by 25.81% to $957000.0 in 2023, then skyrocketed by 184.22% to $2.7 million in 2024, then skyrocketed by 215.29% to $8.6 million in 2025.
  • Business Quant data shows Shares Issued for KNSA at $8.6 million in Q4 2025, $16.3 million in Q3 2025, and $12.7 million in Q2 2025.